Interleukin 32 participates in cardiomyocyte‑induced oxidative stress, inflammation and apoptosis during hypoxia/reoxygenation via the NOD2/NOX2/MAPK signaling pathway

Li,Yuanyuan; Wang,Zhongyan

doi:10.3892/etm.2022.11504

Interleukin 32 participates in cardiomyocyte‑induced oxidative stress, inflammation and apoptosis during hypoxia/reoxygenation via the NOD2/NOX2/MAPK signaling pathway

Authors:
- Yuanyuan Li
- Zhongyan Wang
View Affiliations

Affiliations: Department of Cardiovascular Surgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China, Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: July 12, 2022 https://doi.org/10.3892/etm.2022.11504
Article Number: 567
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although reperfusion of the ischemic myocardium has been used as a vital treatment of various patients with cardiovascular disease, the accompanying myocardial ischemia‑reperfusion injury (MIRI) can cause further damage, resulting in a poor prognosis. The present study aimed to explore the roles and regulatory mechanisms of interleukin (IL)‑32, a pro‑inflammatory cytokine, in MIRI. Cardiomyocytes were subjected to hypoxia and reoxygenation (H/R) to mimic MIRI. The effects of IL‑32 on oxidative stress, inflammation and apoptosis of H/R‑treated cells were assessed. Given that the nucleotide‑binding oligomerization domain 2 (NOD2) and NADPH oxidase 2 (NOX2) play roles in the inflammatory response and myocardial ischemia, the role of this regulatory axis in the function of IL‑32 was evaluated. The results indicated that IL‑32 levels were elevated following H/R treatment. Downregulation of IL‑32 expression attenuated H/R‑induced reduction in cell viability, LDH release, oxidative stress, inflammation and apoptosis. Moreover, downregulation of IL‑32 expression reversed the activation of the NOD2/NOX2/MAPK signaling pathway caused by H/R treatment. NOD2 overexpression altered the effects of the downregulation of IL‑32 expression on the cells, indicating that this regulatory axis mediated the function of IL‑32. Collectively, the data indicated that IL‑32 participated in the induction of oxidative stress, inflammation, and apoptosis in cardiomyocytes during H/R treatment via the NOD2/NOX2/MAPK signaling pathway.

View Figures

View References

1	Sethi NJ, Safi S, Korang SK, Hróbjartsson A, Skoog M, Gluud C and Jakobsen JC: Antibiotics for secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2(CD003610)2021.PubMed/NCBI View Article : Google Scholar
2	Stolpe S, Kowall B and Stang A: Decline of coronary heart disease mortality is strongly effected by changing patterns of underlying causes of death: An analysis of mortality data from 27 countries of the WHO European region 2000 and 2013. Eur J Epidemiol. 36:57–68. 2021.PubMed/NCBI View Article : Google Scholar
3	Woodruff RC, Casper M, Loustalot F and Vaughan AS: Unequal local progress towards healthy people 2020 objectives for stroke and coronary heart disease mortality. Stroke. 52:e229–e232. 2021.PubMed/NCBI View Article : Google Scholar
4	Aday AW and Matsushita K: Epidemiology of peripheral artery disease and polyvascular disease. Circ Res. 128:1818–1832. 2021.PubMed/NCBI View Article : Google Scholar
5	Hagström E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, López-Sendón J, Pella D, Soffer J, Sy R, et al: Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 283:83–92. 2018.PubMed/NCBI View Article : Google Scholar
6	Saito Y and Kobayashi Y: Update on antithrombotic therapy after percutaneous coronary intervention. Intern Med. 59:311–321. 2020.PubMed/NCBI View Article : Google Scholar
7	Bakaeen FG, Gaudino M, Whitman G, Doenst T, Ruel M, Taggart DP, Stulak JM, Benedetto U, Anyanwu A, Chikwe J, et al: 2021: The American association for thoracic surgery expert consensus document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. J Thorac Cardiovasc Surg. 162:829–850.e1. 2021.PubMed/NCBI View Article : Google Scholar
8	Chiang CY, Choi KC, Ho KM and Yu SF: Effectiveness of nurse-led patient-centered care behavioral risk modification on secondary prevention of coronary heart disease: A systematic review. Int J Nurs Stud. 84:28–39. 2018.PubMed/NCBI View Article : Google Scholar
9	Zheng J, Chen P, Zhong J, Cheng Y, Chen H, He Y and Chen C: HIF-1α in myocardial ischemia-reperfusion injury (review). Mol Med Rep. 23(352)2021.PubMed/NCBI View Article : Google Scholar
10	Shen Y, Liu X, Shi J and Wu X: Involvement of Nrf2 in myocardial ischemia and reperfusion injury. Int J Biol Macromol. 125:496–502. 2019.PubMed/NCBI View Article : Google Scholar
11	Xiang M, Lu Y, Xin L, Gao J, Shang C, Jiang Z, Lin H, Fang X, Qu Y, Wang Y, et al: Role of Oxidative stress in reperfusion following myocardial ischemia and its treatments. Oxid Med Cell Longev. 2021(6614009)2021.PubMed/NCBI View Article : Google Scholar
12	Han S and Yang Y: Interleukin-32: Frenemy in cancer? BMB Rep. 52:165–174. 2019.PubMed/NCBI View Article : Google Scholar
13	Kang JY and Kim KE: Prognostic value of interleukin-32 expression and its correlation with the infiltration of natural killer cells in cutaneous melanoma. J Clin Med. 10(4691)2021.PubMed/NCBI View Article : Google Scholar
14	Yao Q, Wang B, Jia X, Li Q, Yao W and Zhang JA: Increased human interleukin-32 expression is related to disease activity of graves' disease. Front Endocrinol (Lausanne). 10(613)2019.PubMed/NCBI View Article : Google Scholar
15	de Albuquerque R, Komsi E, Starskaia I, Ullah U and Lahesmaa R: The role of interleukin-32 in autoimmunity. Scand J Immunol. 93(e13012)2021.PubMed/NCBI View Article : Google Scholar
16	Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA and Kim SH: Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 105:3515–3520. 2008.PubMed/NCBI View Article : Google Scholar
17	Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA and van den Berg WB: IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 103:3298–3303. 2006.PubMed/NCBI View Article : Google Scholar
18	Dinarello CA and Kim SH: IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 65 (Suppl 3):iii61–iii64. 2006.PubMed/NCBI View Article : Google Scholar
19	Cheng Y, Cheng L, Gao X, Chen S, Wu P, Wang C and Liu Z: Covalent modification of Keap1 at Cys77 and Cys434 by pubescenoside a suppresses oxidative stress-induced NLRP3 inflammasome activation in myocardial ischemia-reperfusion injury. Theranostics. 11:861–877. 2021.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Teo KK and Rafiq T: Cardiovascular risk factors and prevention: A perspective from developing countries. Can J Cardiol. 37:733–743. 2021.PubMed/NCBI View Article : Google Scholar
22	Gagno G, Ferro F, Fluca AL, Janjusevic M, Rossi M, Sinagra G, Beltrami AP, Moretti R and Aleksova A: From brain to heart: Possible role of amyloid-β in ischemic heart disease and ischemia-reperfusion injury. Int J Mol Sci. 21(9655)2020.PubMed/NCBI View Article : Google Scholar
23	Qin Z, Shen S, Qu K, Nie Y and Zhang H: Mild hypothermia in rat with acute myocardial ischaemia-reperfusion injury complicating severe sepsis. J Cell Mol Med. 25:6448–6454. 2021.PubMed/NCBI View Article : Google Scholar
24	Tsai CL, Chiu YM, Lee YJ, Hsieh CT, Shieh DC, Tsay GJ, Bau DT and Wu YY: Interleukin-32 plays an essential role in human calcified aortic valve cells. Eur Cytokine Netw. 29:36–47. 2018.PubMed/NCBI View Article : Google Scholar
25	Mann JK, Shen J and Park S: Enhancement of muramyl dipeptide-dependent NOD2 activity by a self-derived peptide. J Cell Biochem. 118:1227–1238. 2017.PubMed/NCBI View Article : Google Scholar
26	Okanishi H, Hayashi K, Sakamoto Y, Sano T, Maruyama H, Kagawa Y and Watari T: NOD2 mRNA expression and NFkappaB activation in dogs with lymphocytic plasmacytic colitis. J Vet Intern Med. 27:439–444. 2013.PubMed/NCBI View Article : Google Scholar
27	Zhang Y, Murugesan P, Huang K and Cai H: NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. Nat Rev Cardiol. 17:170–194. 2020.PubMed/NCBI View Article : Google Scholar
28	Cadenas S: ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 117:76–89. 2018.PubMed/NCBI View Article : Google Scholar
29	Huang W, Xiong Y, Chen Y, Cheng Y and Wang R: NOX2 is involved in CB2-mediated protection against lung ischemia-reperfusion injury in mice. Int J Clin Exp Pathol. 13:277–285. 2020.PubMed/NCBI
30	Pejenaute Á, Cortés A, Marqués J, Montero L, Beloqui Ó, Fortuño A, Martí A, Orbe J and Zalba G: NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis. Int J Mol Sci. 21(1434)2020.PubMed/NCBI View Article : Google Scholar
31	Sirker A, Murdoch CE, Protti A, Sawyer GJ, Santos CX, Martin D, Zhang X, Brewer AC, Zhang M and Shah AM: Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. J Mol Cell Cardiol. 98:11–17. 2016.PubMed/NCBI View Article : Google Scholar
32	Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015.PubMed/NCBI View Article : Google Scholar
33	Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 19:1997–2007. 2020.PubMed/NCBI View Article : Google Scholar
34	Niogret C, Birchmeier W and Guarda G: SHP-2 in lymphocytes' cytokine and inhibitory receptor signaling. Front Immunol. 10(2468)2019.PubMed/NCBI View Article : Google Scholar
35	Lavoie H, Gagnon J and Therrien M: ERK signalling: A master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 21:607–632. 2020.PubMed/NCBI View Article : Google Scholar
36	Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH and Park MH: Interleukin 32, inflammation and cancer. Pharmacol Ther. 174:127–137. 2017.PubMed/NCBI View Article : Google Scholar